N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

In Stock•Starting at $346 for 5 mg

CAS No.	1693734-80-3
MDL No.	N/A
MF	C₃₂H₃₂FN₅O₄
MW	569.60
InChI Key	UBALMDIKIGDHJW-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability
5 mg	To Be Confirmed	$346	In Stock
10 mg	To Be Confirmed	$548	In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1693734-80-3
Product Name	N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

Health Hazard

Environmental Hazard

Signal Word:Warning

HCode:H341-H411

PCode:P203-P273-P280-P318-P391-P405-P501

N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

In Stock•Starting at $346 for 5 mg

CAS No.	1693734-80-3
MDL No.	N/A
MF	C₃₂H₃₂FN₅O₄
MW	569.60
InChI Key	UBALMDIKIGDHJW-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability
5 mg	To Be Confirmed	$346	In Stock
10 mg	To Be Confirmed	$548	In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1693734-80-3
Product Name	N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

Health Hazard

Environmental Hazard

Signal Word:Warning

HCode:H341-H411

PCode:P203-P273-P280-P318-P391-P405-P501

N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

Pricing & Availability

Product Information

Safety Information

Properties

N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

Pricing & Availability

Product Information

Safety Information

Properties

Documentation

N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma.

Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1/HSPB1 pathway.

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.

The form and function of cnidarian spirocysts. 2. Ultrastructure of the capsule tip and wall and mechanism of discharge.

N-(5-(2,3-dihydrobenzo(b)(1,4)dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma.

Gandouling ameliorates liver injury in Wilson's disease through the inhibition of ferroptosis by regulating the HSF1/HSPB1 pathway.

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.

The form and function of cnidarian spirocysts. 2. Ultrastructure of the capsule tip and wall and mechanism of discharge.

Documentation